http://livestream.com/nasdaq/live
$DMPI DelMar Pharmaceuticals ring the opening bell @ Nasdaq
Recent KTRA News
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 01:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:05:08 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:13 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/12/2024 09:01:34 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/08/2024 09:30:36 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/19/2024 09:03:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:17:26 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 07/08/2024 10:45:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 10:40:09 AM
- TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor • PR Newswire (US) • 07/08/2024 10:30:00 AM
- Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term Milestones • PR Newswire (US) • 07/01/2024 12:35:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/13/2024 08:10:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:05:11 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 06/03/2024 12:50:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:45:11 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Positive Results from Phase 1b Trial of IFx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) • PR Newswire (US) • 06/03/2024 12:35:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/17/2024 08:05:37 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 05/14/2024 08:55:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:50:14 PM
- Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results • PR Newswire (US) • 05/14/2024 08:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:40:36 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 05/13/2024 08:06:50 PM
- Kuehn Law Encourages KTRA, ABIO, SWAV, and NS Investors to Contact Law Firm • PR Newswire (US) • 04/05/2024 05:09:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM